Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

CONCLUSIONS: Prostate SBRT has substantial prospective evidence supporting its use, with favorable tumor control, patient-reported QOL, and toxicity demonstrated. SBRT has sufficient evidence to be supported as a standard treatment option for localized prostate cancer, while ongoing trials assess its potential superiority.
PMID: 30959121 [PubMed - as supplied by publisher]

Source: Physics in Medicine and Biology - April 4, 2019 Category: Physics Authors: Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE Tags: Int J Radiat Oncol Biol Phys Source Type: research